Skip to main content
Premium Trial:

Request an Annual Quote

Cellectis Licenses TAL-effector Patents from University of Minnesota

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Cellectis today announced a licensing agreement with the University of Minnesota giving it exclusive rights to use inventions related to TAL effector-mediated DNA recognition and cleavage.

Financial and other terms of the deal were not disclosed.

The technology was co-developed at the University of Minnesota and Iowa State University, and in a statement, Cellectis said that it shows promising results in genome engineering. It is complementary to Cellectis' proprietary meganuclease technology, the Paris-based genome engineering firm added.

The Scan

Not as High as Hoped

The Associated Press says initial results from a trial of CureVac's SARS-CoV-2 vaccine suggests low effectiveness in preventing COVID-19.

Finding Freshwater DNA

A new research project plans to use eDNA sampling to analyze freshwater rivers across the world, the Guardian reports.

Rise in Payments

Kaiser Health News investigates the rise of payments made by medical device companies to surgeons that could be in violation of anti-kickback laws.

Nature Papers Present Ginkgo Biloba Genome Assembly, Collection of Polygenic Indexes, More

In Nature this week: a nearly complete Ginkgo biloba genome assembly, polygenic indexes for dozens of phenotypes, and more.